Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab

  • Oncoimmunology. 2015 Mar 24;4(7):e1011524. doi: 10.1080/2162402X.2015.1011524.
Xiao Ni  1 ,  Timothy Langridge  1 ,  Madeleine Duvic  1
Affiliations
  • 1. Department of Dermatology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.
PMID: 26140234 DOI: 10.1080/2162402X.2015.1011524
Abstract

The CC Chemokine Receptor 4 (CCR4) is highly expressed on type 2 helper T cells and regulatory T (Treg) cells. Mogamulizumab, an anti-CCR4 antibody, reduces the numbers of CCR4+ malignant T cells and CCR4+ Treg cells in cutaneous T-cell lymphoma. Depleting Treg cells by targeting CCR4 has great potential in Cancer immunotherapies.

Keywords
Sézary syndrome; chemokine receptor; cutaneous T-cell lymphoma; mogamulizumab; monoclonal antibody; mycosis fungoides; regulatory T cells; targeted therapy.